Table 2.
Response according to treatment
| Therapy | Patients, n | ≥vgPR% | ORR% | vgPR, n | CR, n | PR, n | SD, n | PD, n |
|---|---|---|---|---|---|---|---|---|
| All treatments | 50 | 38 | 76 | 11 | 8 | 19 | 3 | 9 |
| Bortezomib-based, no ASCT | 23 | 26 | 70 | 4 | 2 | 10 | 2 | 5 |
| Bortezomib-based, +ASCT | 15 | 73 | 100 | 6 | 5 | 4 | – | – |
| Conventional treatment (including 2 MPT) | 12 | 17 | 58 | 1 | 1 | 5 | 1 | 4 |
vgPR very good partial response, ORR objective response rate, CR complete response, PR partial response, SD stable disease, PD progressive disease, ASCT autologous transplantation, MPT melphalan, prednisone, thalidomide